Department of Neuro Oncology

Publications (428)

• Article: Chapter 13 Autophagy Pathways in Glioblastoma

  Hong Jiang, Erin J. White, Charles Conrad, Candelaria Gomez-Manzano, Juan Fueyo
  Methods in Enzymology. 453:273-286.
• Article: Atypical spasmus nutans as an initial sign of thalamic neoplasm.

  T Z Baram, R Tang
  Pediatric Neurology 2(6):375-6. · 1.52 Impact Factor
• Article: Convenient preparation of 4-(tetrazol-5-yl)-phenylalanine for use in Fmoc-based solid-phase peptide synthesis

  John S McMurray, Olga Khabashesku, James S Birtwistle, Wei Wang
  Tetrahedron Letters 41(34):6555-6558. · 2.68 Impact Factor
• Article: Stereospecific synthesis of 4-carboxyphenylalanine and derivatives for use in Fmoc-based solid-phase peptide synthesis

  Wei Wang, Nihal U. Obeyesekere, John S. McMurray
  Tetrahedron Letters 37(37):6661-6664. · 2.68 Impact Factor
• Article: Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.

  John F de Groot, Wai Kwan Alfred Yung
  The Cancer Journal 14(5):279-85. · 3.26 Impact Factor
• Article: Narcotics and cancer pain control.

  C S Hill
  CA A Cancer Journal for Clinicians 38(6):322-6. · 101.78 Impact Factor
• Article: Influence of acidic residues on substrate specificity of oncogene products pp60v-src and p56lck in vitro.

  D A Tinker, J L Cartron, J S McMurray, V A Levin
  Anticancer research 12(1):123-7. · 1.73 Impact Factor
• Article: New frontiers in therapy of malignant gliomas.

  V K Puduvalli, A W Yung
  Forum (Genoa, Italy) 8(3):261-9.
• Article: Treatment of respiratory dyskinesia with olanzapine.

  J Gotto
  Psychosomatics 40(3):257-9. · 2.12 Impact Factor
• Article: Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling.

  C H Rhee, S Ruan, S Chen, A Chenchik, V A Levin, A W Yung, G N Fuller, W Zhang
  Oncology Reports 6(2):393-401. · 1.84 Impact Factor
• Article: Terminally ill cancer patients. Their most important concerns.

  A J Greisinger, R J Lorimor, L A Aday, R J Winn, W F Baile
  Cancer Practice 5(3):147-54.
• Article: Influence of solid support, solvent and coupling reagent on the head-to-tail cyclization of resin-bound peptides.

  J S McMurray, C A Lewis, N U Obeyesekere
  Peptide research 7(4):195-206.
• Article: Cyclooxygenase-2 inhibitors in glioma therapy.

  Pierre Giglio, Victor Levin
  American Journal of Therapeutics 11(2):141-3. · 1.49 Impact Factor
• Article: Cytogenetic and molecular abnormalities in astrocytic gliomas (Review).

  A C Goussia, N J Agnantis, J S Rao, A P Kyritsis
  Oncology Reports 7(2):401-12. · 1.84 Impact Factor
• Source

  Available from: moffittcancercenter.org

  Article: Advances in molecular therapies in patients with brain tumors.

  Ivo W Tremont-Lukats, Mark R Gilbert
  Cancer control: journal of the Moffitt Cancer Center 10(2):125-37.
• Article: Chemotherapy and cognition: effects, potential mechanisms, and management.

  Anne E Kayl, Jeffrey S Wefel, Christina A Meyers
  American Journal of Therapeutics 13(4):362-9. · 1.49 Impact Factor
• Article: Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

  W K Yung, P A Steck, P J Kelleher, R P Moser, M G Rosenblum
  Journal of Neuro-Oncology 02/1987; 5(4):323-30. · 3.21 Impact Factor
• Source

  Available from: aacrjournals.org

  Article: Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

  P A Steck, P Lee, M C Hung, W K Yung
  Cancer Research 11/1988; 48(19):5433-9. · 7.86 Impact Factor
• Article: In vitro chemosensitivity testing and its clinical application in human gliomas.

  W K Yung
  Neurosurgical Review 02/1989; 12(3):197-203. · 2.04 Impact Factor
• Source

  Available from: aacrjournals.org

  Article: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells.

  W K Yung, R Lotan, P Lee, D Lotan, P A Steck
  Cancer Research 03/1989; 49(4):1014-9. · 7.86 Impact Factor
• Source

  Available from: aacrjournals.org

  Article: Altered expression and distribution of heparan sulfate proteoglycans in human gliomas.

  P A Steck, R P Moser, J M Bruner, L Liang, A N Freidman, T L Hwang, W K Yung
  Cancer Research 05/1989; 49(8):2096-103. · 7.86 Impact Factor
• Article: Pain management in a drug-oriented society.

  C S Hill
  Cancer 07/1989; 63(11 Suppl):2383-6. · 4.77 Impact Factor
• Article: Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.

  W K Yung, M I Harris, J M Bruner, L G Feun
  Journal of Neuro-Oncology 10/1989; 7(3):237-40. · 3.21 Impact Factor
• Article: The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen.

  B L Maria, P A Steck, W K Yung, A Milici, J M Bruner, S Pathak, F F Becker
  Journal of Neuro-Oncology 12/1989; 7(4):329-38. · 3.21 Impact Factor
• Article: Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction.

  H Saya, S Ara, P S Lee, J Ro, M C Hung
  Molecular Carcinogenesis 02/1990; 3(4):198-201. · 3.16 Impact Factor
• Article: Differential amplification of the TGF-alpha gene in human gliomas.

  W K Yung, X Zhang, P A Steck, M C Hung
  Cancer communications 02/1990; 2(6):201-5.
• Article: Peripheral neuropathy in cancer patients: incidence, features, and pathophysiology.

  A Forman
  Oncology (Williston Park, N.Y.) 02/1990; 4(1):57-62 concl. · 1.03 Impact Factor
• Article: Peripheral neuropathy in cancer patients: clinical types, etiology, and presentation. Part 2.

  A Forman
  Oncology (Williston Park, N.Y.) 03/1990; 4(2):85-9. · 1.03 Impact Factor
• Article: Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells.

  P A Steck, A Hadi, R Lotan, W K Yung
  Journal of Cellular Biochemistry 03/1990; 42(2):83-94. · 2.87 Impact Factor
• Article: Neurologic complications of polycythemia and their impact on therapy.

  L K Newton
  Oncology (Williston Park, N.Y.) 04/1990; 4(3):59-64; discussion 64-6. · 1.03 Impact Factor
• Article: Modification of a commercially available method of extracting plasmid DNA.

  P S Lee, S Ara, H Saya
  BioTechniques 05/1990; 8(4):386. · 2.67 Impact Factor
• Article: Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment.

  C A Meyers, R S Scheibel
  Oncology (Williston Park, N.Y.) 08/1990; 4(7):115-22; discussion 122, 126-7, 130. · 1.03 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Codon 72 polymorphism of the TP53 gene.

  S Ara, P S Lee, M F Hansen, H Saya
  Nucleic Acids Research 09/1990; 18(16):4961. · 8.03 Impact Factor
• Article: A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.

  W K Yung, A M Castellanos, P Van Tassel, R P Moser, S G Marcus
  Journal of Neuro-Oncology 09/1990; 9(1):29-34. · 3.21 Impact Factor
• Article: Chemotherapy for malignant brain tumors.

  W K Yung
  Current Opinion in Oncology 09/1990; 2(4):673-8. · 4.10 Impact Factor
• Article: Growth regulatory activities of endothelial extracellular matrix: mediation by transforming growth factor-beta.

  L K Newton, W K Yung, L C Pettigrew, P A Steck
  Experimental Cell Research 10/1990; 190(1):127-32. · 3.58 Impact Factor
• Article: Leptomeningeal carcinomatosis.

  A Forman
  American Journal of Clinical Oncology 01/1991; 13(6):536-40. · 2.01 Impact Factor
• Article: Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction.

  K Oka, J Ishikawa, J M Bruner, R Takahashi, H Saya
  Molecular Carcinogenesis 02/1991; 4(1):10-3. · 3.16 Impact Factor
• Article: Persistent neurotoxicity of systemically administered interferon-alpha.

  C A Meyers, R S Scheibel, A D Forman
  Neurology 06/1991; 41(5):672-6. · 8.31 Impact Factor
• Article: Intravenous carboplatin for recurrent malignant glioma: a phase II study.

  W K Yung, L Mechtler, M J Gleason
  Journal of Clinical Oncology 06/1991; 9(5):860-4. · 18.37 Impact Factor
• Article: Pathways of oncogenesis in primary brain tumors.

  P A Steck, H Saya
  Current Opinion in Oncology 07/1991; 3(3):476-84. · 4.10 Impact Factor
• Article: Inhibition of adenylate cyclase by tetraplatin.

  B T Ho, Y Y Huo, J H Lee, V A Levin
  Anti-Cancer Drugs 07/1991; 2(3):267-8. · 2.41 Impact Factor
• Article: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease.

  C A Meyers, E A Obbens, R S Scheibel, R P Moser
  Cancer 08/1991; 68(1):88-92. · 4.77 Impact Factor
• Article: Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.

  T Nishi, P S Lee, K Oka, V A Levin, S Tanase, Y Morino, H Saya
  Oncogene 10/1991; 6(9):1555-9. · 6.37 Impact Factor
• Article: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study.

  W K Yung, M Prados, V A Levin, M R Fetell, J Bennett, M S Mahaley, M Salcman, E Etcubanas
  Journal of Clinical Oncology 12/1991; 9(11):1945-9. · 18.37 Impact Factor
• Article: Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA.

  H Mochizuki, T Nishi, J M Bruner, P S Lee, V A Levin, H Saya
  Molecular Carcinogenesis 02/1992; 6(2):83-7. · 3.16 Impact Factor
• Article: An assay for acidic peptide substrates of protein kinases.

  R J Budde, J S McMurray, D A Tinker
  Analytical Biochemistry 03/1992; 200(2):347-51. · 3.00 Impact Factor
• Article: Cognitive functioning in cancer patients: effect of previous treatment.

  C A Meyers, J L Abbruzzese
  Neurology 03/1992; 42(2):434-6. · 8.31 Impact Factor
• Article: The intractable pain treatment act of Texas.

  C S Hill
  Texas medicine 03/1992; 88(2):70-2.
• Article: Analgesic activity of anticancer agent suramin.

  B T Ho, Y Y Huo, J G Lu, R A Newman, V A Levin
  Anti-Cancer Drugs 05/1992; 3(2):91-4. · 2.41 Impact Factor